Icon awarded FDA project to validate PRO instruments

By Melissa Fassbender

- Last updated on GMT

Icon awarded FDA project to validate PRO instruments

Related tags Contract research organization

The US Food & Drug Administration (FDA) has tasked Icon plc to validate three patient-reported outcomes (PRO) instruments in antibacterial drug trials.

Icon’s Clinical Outcomes Assessment (COA) group and the Biomarkers Consortium of the Foundation for the National Institutes of Health (FNIH) will collaborate on an electronic platform to validate the PROs – allowing investigators to evaluate symptoms and measure the effects of antibacterial drugs.

According to the contract research organization (CRO), the specific conditions in which the endpoints will be validated, include Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP), and Hospital-Acquired Bacterial Pneumonia (HABP).

Through the trials, patients will use a handheld device​ with PROs to be implemented on CRF Health’s TrialMax® eCOA platform.

These PROs will continue to be validated and developed in accordance with the FDA guidance for PRO measures used to support labeling claims and will follow the Drug Development Tool (DDT) Qualification Program​,” the company said.

The FDA previously selected​ Icon to develop new PRO instruments in November 2014.

(Feature image: iStock/zozzzzo)

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us

Products

View more

Webinars